Summary In vitro drug sensitivity of leukaemic cells might be influenced by the contamination of such a sample with non-malignant cells and the sample source. To study this, sensitivity of normal peripheral blood (PB) lymphocytes to a number of cytostatic drugs was assessed with the MTT assay. We compared this sensitivity with the drug sensitivity of leukaemic cells of 38 children with acute lymphoblastic leukaemia. We also studied a possible differential sensitivity of leukaemic cells from bone marrow (BM) and PB. The following drugs were used: Prednisolone, dexamethasone, 6-mercaptopurine, 6-thioguanine, cytosine arabinoside, vincristine, vindesine, daunorubicin, doxorubicin, mafosfamide (Maf), 4-hydroperoxy-ifosfamide, teniposide, mitoxantrone, L-asparaginase, methotrexate and mustine.
Differences in sensitivity to cytostatic drugs between normal and malignant cells are important for a number of reasons. In the first place, the clinical use of drugs with a preferential toxicity towards malignant cells is preferred. Secondly, the success of pharmacologic bone marrow (BM) purging of malignant cells before autologous BM transplantation, currently intensively studied and practised (Kluin-Nelemans et al., 1984; Rizzoli et al., 1990; Scholzel et al., 1986; Singer & Linch, 1987) , depends on malignant cells being more sensitive to the drugs applied than normal haematopoietic stem cells. Finally, one should know the drug sensitivity of normal cells, to determine the influence of their presence in a malignant tumour sample of which in vitro drug sensitivity is assessed.
A tetrazolium-based assay to study in vitro antitumour activity of cytostatic drugs was described almost 40 years ago (Black & Speer, 1953) . A similar assay is the MTT assay, in the English literature first described by Mosmann (1983) . The MTT assay is a valulable drug sensitivity assay (Veerman & Pieters, 1990) . In this assay no distinction can be made between different kinds of living cells in the sample tested (Pieters et al., 1988) . Therefore, the presence of a substantial number of normal cells might influence the results (Kirkpatrick et al., 1990) .
In studies of drug resistance in leukaemic patients, both BM and peripheral blood (PB) samples are investigated. Prior to the collective evaluation of the results, one should rule out the possibility that BM and PB leukaemic cells differ in drug sensitivity. Therefore, we determined and compared the in vitro sensitivity of normal PB lymphocytes and leukaemic cells from BM and PB of children with acute leukaemia to 16 cytostatic drugs.
Materials and methods

Reagents
Prednisolone disodiumphosphate (PRD), dexamethasone disodiumphosphate (DXM), daunorubicin (DNR), L-asparaginase (L-Asp), mustine hydrochloride (Must), cytosine arabinoside (Ara-C), vindesine (VDS), vincristine (VCR), mitoxantrone (Mitox), methotrexate (MTX), and teniposide (Teni) were obtained from our hospital pharmacy, together with acidified (0.04 N HCI) isopropanol; 6-thioguanine (6-TG), 6-mercaptopurine (6-MP), and doxorubicin (Dox) from Sigma; mafosfamide (Maf, and 4-hydroperoxy-ifosfamide (4-HI), active derivatives of cyclofosfamide (CFM) and ifosfamide (IFM) respectively, were kindly provided by ASTA Pharma AG (Dr M. Peukert, Bielefeld, Germany).
PRD (of which 75% corresponds to pure prednisolone) was dissolved in saline. DNR, L-Asp, Must, VDS, and Dox were dissolved in distilled water, 6-MP and 6-TG in 0.1 N NaOH, Maf in PBS, and 4-HI in DMSO/distilled water (1:1 Figure 1 for normal PB lymphocytes. In the wells, 20 yl of the various drug solutions was dispensed already. Each drug was tested in six concentrations, in duplicate (Table I) . Because we observed evaporation in the outer wells, these were filled with RPMI. Six wells containing medium only were used for blanking the reader, another six wells containing cells and medium were used to determine the control cell survival. The plates were incubated in humidified air containing 5% CO2
for 4 days at 37°C. Then 10 gl MTT solution (5 mg ml-') was added and after shaking the plates until the cell pellet was dissolved, they were incubated for 6 h. The formed formazan crystals were dissolved with 100 jil isopropanol. Dexamethasonea ( might be explained by the differences in assays, drug concentrations and cells used. We demonstrated, using the MTT assay, that normal PB lymphocytes are significantly more resistant to PRD, DXM, 6-MP, 6-TG, VCR, DNR, Ara-C, VDS, Teni, L-Asp, Mitox and Dox than leukaemic cells of children with ALL, also when only leukaemic samples from the PB were evaluated (Table II) . We did not find a significantly greater sensitivity of the BM and PB leukaemic cells to Maf (an active metabolite of CFM), in accordance with the results of KluinNelemans et al. (1984) and Singer and Linch (1987) . In two out of three studies using melphalan, another alkylating agent, again an equal sensitivity of non-malignant and leukaemic cells was reported (Spiro et al., 1981a; Singer & Linch, 1987) . These observations suggest that alkylating agents have a less favourable therapeutic index. Their value in BM purging -based on direct cytotoxic activity -seems to be small. This does not necessarily implicate that these drugs are not useful in this respect. Recently, Rizzoli et al. (1990) reported a beneficial effect of BM puring with Maf (in individually adjusted doses) on leukaemic free survival after autologous-purged -BM transplantation and suggested this could be due to activation of immunological systems able to control minimal residual disease in vivo, and not primarily to the direct cytotoxic activity of the drug during the purging procedure. The wide range of drug sensitivity of leukaemic cells from different patients, implies the necessity of individually adjusted doses of cytostatic drugs for optimal BM purging, as indeed has been reported to be more successful than standard purging (Rizzoli et al., 1990) .
The cause(s) of the presented differential drug sensitivity of normal lymphocytes and leukaemic cells are largely unknown. However, these cells differ in several aspects, like immunophenotype and differentiation-stage. Normal PB lymphocytes are mainly of the T-lineage (which was even more accentuated after the 4-days incubation period of the MTT assay in the present study) and represent mature cells. Most childhood actue leukaemias are of the immature B-lineage phenotype, as was the case in this study. The T-lineage leukaemias show a less mature phenotype than normal Tcells. Recently we found that T-ALL cells were relatively resistant to various drugs compared to immature B-ALL cells (Pieters et al., in press ). Therefore, the differences regarding immunophenotype between the tested leukaemic and normal lymphocytes could well contribute to the presented differences in drug sensitivity. Changes in immunophenotype of normal lymphocytes might occur in patients suffering a malignancy. However, we found that the removal of normal T-lymphocytes from ALL samples with less than 80% ALL cells resulted in increased drug sensitivity (unpublished data). This supports the conclusions of the present study. An extensive discussion of all other possible causes of the presented difference in drug sensitivity is beyond the scope of this report.
The analysis of the assay results obtained with (unpaired) BM and PB leukaemic cells from all 38 ALL patients did not reveal a preferential sensitivity of the PB or BM leukaemic cells to any of the drugs (Table III) . Similarly, no preferential sensitivity of the (paired) BM or PB leukaemic cells from 12 leukaemic patients (one ANLL, 11 ALL) was found. In 11 out of 12 patients of whom we tested their (paired) BM and PB leukaemic cells, the sample source did not significantly influence drug sensitivity. In one case the leukaemic cells from the BM were significantly more sensitive than those from the PB, but the actual differences in LCm values were very small and of no practical importance. The correlation for all 106 paired BM and PB LC50 comparisons was very good, with most pairs close to the ideal line x = y (Figure 3 ). Our findings agree with those of Bird et al. (1986) , who reported a significant association in sensitivity to a maximum of six drugs of leukaemic BM and PB cells from 12 patients. The same was found by Sargent and Taylor (1989) and Spiro et al. (1981a) , in single cases.
We conclude that normal PB lymphocytes are more resistant than childhood ALL cells to a large number of drugs in vitro. Consequently, the number of normal lymphocytes contaminating an ALL sample to be tested should be low, when the MTT assay or a similar total cell kill assay is used. This is especially the case in view of the higher survival at day 4 and the higher MTT reduction per living cell of the normal lymphocytes compared to the untreated ALL cells. The MIT assay and the Differential Staining Cytotoxicity (DiSC) assay gave comparable results in samples with 80% (or more) leukaemic cells, the lowest percentage tested (Pieter et al., 1989) . Therefore, in case of a sample with less than 80% leukaemic cells, the use of the DiSC assay -in which a distinction between non-malignant and leukaemic cells can be made -should be considered. Because this assay is laborious and subjective, we are investigating techniques to remove non-malignant cells from leukaemic samples.
Finally, because the drug sensitivity profiles of leukaemic cells from the BM are quite comparable to those from the PB, it is allowed to evaluate results obtained using samples from both sources together, which obviously is of practical importance.
